U.S. regulators imposed a combined $80 million penalty on Canaccord Genuity LLC, the U.S. arm of Vancouver-based Canaccord Genuity Group Inc., for systemic failures in its anti-money laundering (AML) program that allowed suspicious trading to go unreported. The settlement involves the Securities and Exchange Commission (SEC), Financial Industry Regulatory Authority (FINRA), and Financial Crimes Enforcement Network (FinCEN), marking FinCEN’s largest-ever fine against a broker-dealer for Bank Secrecy Act (BSA) violations. Canaccord admitted to willful BSA breaches, including inadequate surveillance, poor customer due diligence, and failure to file over 150 suspicious activity reports (SARs) spanning years of high-risk equity trading.
The violations centered on Canaccord’s role as a major market maker in over-the-counter (OTC) securities, particularly low-priced penny stocks prone to manipulation like wash trading and pump-and-dump schemes. From February 2019 to March 2022, the SEC found Canaccord’s AML surveillance relied on flawed exception reports that failed to capture key data, with compliance staff overwhelmed and delays leaving thousands of alerts unreviewed for months or years. One critical “low volume” report monitoring vulnerable penny stocks went unreviewed from June 2019 to March 2022, enabling unchecked manipulative patterns.
FinCEN’s assessment extended from March 2018 to June 2024, citing 160 unfiled SARs on dozens of OTC stocks involving thousands of suspicious transactions that harmed retail investors. Deficiencies also included weak know-your-client (KYC) and onboarding processes, allowing high-risk clients with ties to Russian oligarchs and Venezuelan sanctioned individuals access to U.S. markets without proper scrutiny. Canaccord’s under-resourced, inexperienced compliance team used poorly designed tools disproportionate to its high-risk business model.
Regulatory Allegations in Detail
The SEC order highlighted how Canaccord’s equity trading business, active in under-$5 OTC securities, lacked a reasonably designed AML program to detect and report suspicious OTC activity. Personnel falsified review documentation on flagged trades from market-making and institutional desks, breaching exchange rules and depriving investigators of vital data. This resulted in approximately 150 missed SARs on potentially manipulative trades.
FinCEN emphasized broader BSA failures: no effective AML program, insufficient due diligence on foreign correspondent accounts, and SAR filing lapses despite repeated regulatory exam findings. Canaccord ignored commitments to fix weaknesses, delaying remediation until the investigation began. Harm included facilitating fraud schemes causing economic losses to innocent investors and enabling illicit actors’ market access.
FINRA’s involvement focused on supervisory lapses, contributing to the $20 million portion of the penalty. The regulators coordinated closely, with FinCEN noting Canaccord’s market-making position uniquely enabled red-flag detection in penny stock scams, yet systemic issues prevailed.
Canaccord’s Response and Remediation
Canaccord stated the $75 million net settlement (C$102.6 million) has no material financial impact and resolves the matters. Lead independent director Michael Auerbach noted a “wholesale change in compliance leadership,” enhanced culture, and constructive regulator engagement. The firm boosted staffing, revamped reports and processes, and hired external consultants for policy reviews—efforts cited by the SEC as supporting the no-fault settlement.
Canaccord self-reported employee falsifications to FINRA and undertook remediation only after probes intensified, per FinCEN. The firm ceased and desisted from violations and faces a censure.
Regulator Statements
FinCEN Director Andrea Gacki called it a “wake-up call” for broker-dealers to protect against illicit actors harming Americans and markets. She stressed risk-based AML proportional to business risks, especially fraud in securities. FinCEN highlighted prompt exam responses and SAR accuracy.
The SEC acknowledged Canaccord’s cooperation and fixes in accepting the deal without further proceedings.
Broader Implications for AML Compliance
This record action underscores escalating U.S. scrutiny on broker-dealers’ AML obligations amid rising securities fraud, particularly in OTC penny stocks. FinCEN’s focus on fraud’s economic harm aligns with Treasury priorities, signaling more penalties for under-resourced programs ignoring exam findings. Firms must ensure surveillance matches high-risk models, with robust CDD for institutional clients under the 2016 CDD Rule.
Canaccord’s Canadian history includes prior FINTRAC and CIRO fines for AML and wash trading issues, highlighting cross-border compliance challenges. The case reinforces whistleblower incentives for BSA tips exceeding $1M penalties. Investors and firms face reminders to monitor for manipulation vulnerabilities.